Immune Design to Report Third Quarter 2014 Financial Results and Provide Corporate Update
SEATTLE and SOUTH SAN FRANCISCO, Calif., Nov. 5, 2014 (GLOBE NEWSWIRE) -- Immune Design Corp. (Nasdaq:IMDZ), a clinical-stage immunotherapy company, today announced that it will report third quarter 2014 financial results before the opening of U.S. financial markets on Wednesday, November 12, 2014. Immune Design management will host a webcast and conference call at 5:30 a.m. PST/8:30 a.m. EST that day to discuss the financial results and provide a corporate update.
The live call may be accessed by dialing 844-831-3023 for domestic callers and 920-663-6275 for international callers. A live webcast of the call will be available online from the investor relations section of the company website at www.immunedesign.com and will be archived there for ninety days. A telephone replay of the call will be available for five days by dialing 855-859-2056 for domestic callers or 404-537-3406 for international callers and entering the conference code: 31434939.
About Immune Design
Immune Design is a clinical-stage immunotherapy company employing next-generation in vivo approaches to enable the body's immune system to fight disease. The company's technologies are engineered to activate the immune system's natural ability to create and/or expand antigen-specific cytotoxic T cells, while enhancing other immune effectors, to fight cancer and other chronic diseases. Immune Design's three on-going immuno-oncology clinical programs are the product of its two synergistic discovery platforms: ZVexTM and GLAASTM. Immune Design has offices in Seattle and South San Francisco. For more information, please visit www.immunedesign.com.
CONTACT: Investor Contact Robert H. Uhl Westwicke Partners email@example.com 858-356-5932 Media Contact Julie Rathbun Rathbun Communications firstname.lastname@example.org 206-769-9219